Understanding the Preclinical Efficacy of Antibody-Drug Conjugates.

ABSTRACT: Antibody-drug conjugates (ADCs) represent a therapeutic modality that guides chemotherapies to tumoral cells by using antibodies against tumor-associated antigens (TAAs). The antibody and the chemotherapy or payload are attached by a chemical structure called the linker. The strategy for the development of this type of drug was based on several rational pillars, including the use of a very potent payload and the use of specific antibodies acting only on antigens expressed on tumoral cells. In this article, by using data from all approved ADCs that have received regulatory approval, we analyze the potential contribution of each ADC component to preclinical activity. We suggest that payload potency and the drug-to-antibody ratio (DAR) have a less relevant role in relation to efficacy than pr

SUBMITTER: Diaz-Tejeiro C 

PROVIDER: S-EPMC11641021 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature